173 related articles for article (PubMed ID: 37986542)
1. Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors.
Kuncewicz M; Jaszczyszyn IP; Karaban K; Rykowski P; Krasnodębski M; Morawski M; Kruk E; Koperski Ł; Zieniewicz K; Krawczyk M; Grąt M
Ann Transplant; 2023 Nov; 28():e941212. PubMed ID: 37986542
[TBL] [Abstract][Full Text] [Related]
2. Outcomes following liver transplantation for metastatic neuroendocrine tumors.
Grąt M; Remiszewski P; Smoter P; Wronka KM; Grąt K; Lewandowski Z; Koperski L; Górnicka B; Pacho R; Zborowska H; Patkowski W; Krawczyk M
Transplant Proc; 2014 Oct; 46(8):2766-9. PubMed ID: 25380913
[TBL] [Abstract][Full Text] [Related]
3. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
4. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for unresectable neuroendocrine tumor liver metastases.
Rossi RE; Burroughs AK; Caplin ME
Ann Surg Oncol; 2014 Jul; 21(7):2398-405. PubMed ID: 24562931
[TBL] [Abstract][Full Text] [Related]
7. Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal.
Eshmuminov D; Studer DJ; Lopez Lopez V; Schneider MA; Lerut J; Lo M; Sher L; Musholt TJ; Lozan O; Bouzakri N; Sposito C; Miceli R; Barat S; Morris D; Oehler H; Schreckenbach T; Husen P; Rosen CB; Gores GJ; Masui T; Cheung TT; Kim-Fuchs C; Perren A; Dutkowski P; Petrowsky H; Thiis-Evensen E; Line PD; Grat M; Partelli S; Falconi M; Tanno L; Robles-Campos R; Mazzaferro V; Clavien PA; Lehmann K
Ann Surg; 2023 May; 277(5):e1063-e1071. PubMed ID: 35975918
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation in patients with liver metastases from neuroendocrine tumors.
Spolverato G; Bagante F; Tsilimigras DI; Pawlik TM
Minerva Chir; 2019 Oct; 74(5):399-406. PubMed ID: 31280548
[TBL] [Abstract][Full Text] [Related]
9. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
[TBL] [Abstract][Full Text] [Related]
10. Younger Age Is Associated with Improved Survival in Patients Undergoing Liver Transplantation Alone for Metastatic Neuroendocrine Tumors.
Valvi D; Mei X; Gupta M; Shah MB; Ancheta A; Marti F; Gedaly R
J Gastrointest Surg; 2021 Jun; 25(6):1487-1493. PubMed ID: 32632728
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
12. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience.
Kose E; Kahramangil B; Aydin H; Donmez M; Takahashi H; Aucejo F; Siperstein A; Berber E
Surg Endosc; 2020 Jan; 34(1):249-256. PubMed ID: 30945061
[TBL] [Abstract][Full Text] [Related]
13. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.
Le Treut YP; Grégoire E; Klempnauer J; Belghiti J; Jouve E; Lerut J; Castaing D; Soubrane O; Boillot O; Mantion G; Homayounfar K; Bustamante M; Azoulay D; Wolf P; Krawczyk M; Pascher A; Suc B; Chiche L; de Urbina JO; Mejzlik V; Pascual M; Lodge JP; Gruttadauria S; Paye F; Pruvot FR; Thorban S; Foss A; Adam R;
Ann Surg; 2013 May; 257(5):807-15. PubMed ID: 23532105
[TBL] [Abstract][Full Text] [Related]
14. Association of lymph node metastases, grade and extent of mesenteric lymph node dissection in locoregional small intestinal neuroendocrine tumors with recurrence-free survival.
Daskalakis K; Wedin M; Tsoli M; Kogut A; Srirajaskanthan R; Sarras K; Kattiparambil S; Giovos G; Weickert MO; Kos-Kudla B; Kaltsas G
J Neuroendocrinol; 2022 Nov; 34(11):e13205. PubMed ID: 36385444
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.
Chao JS; Zhao SL; Ou-Yang SW; Qian YB; Liu AQ; Tang HM; Zhong L; Peng ZH; Xu JM; Sun HC
World J Gastroenterol; 2019 Oct; 25(37):5630-5640. PubMed ID: 31602163
[TBL] [Abstract][Full Text] [Related]
16. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
18. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
19. Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary.
Korda D; Doros A; Piros L; Gerlei Z; Haboub-Sandil A; Mándli T; Fazakas J; Deák ÁP; Máthé Z
Transplant Proc; 2019 May; 51(4):1251-1253. PubMed ID: 31101208
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
Bagante F; Spolverato G; Merath K; Postlewait LM; Poultsides GA; Mullen MG; Bauer TW; Fields RC; Lamelas J; Marques HP; Aldrighetti L; Tran T; Maithel SK; Pawlik TM
J Surg Oncol; 2017 May; 115(6):687-695. PubMed ID: 28146608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
